WALTHAM, Mass., May 02, 2025 (WORLD NEWSWIRE)– Xilio Rehabs, Inc. XLO, a clinical-stage biotechnology business finding and establishing tumor-activated immuno-oncology treatments for individuals dealing with cancer, today revealed that, reliable May 1, 2025, the business gave a non-qualified stock choice to buy 5,000 shares of its typical stock to one brand-new staff member under Xilio Rehabs’ 2022 Temptation Stock Reward Strategy.
The stock choices have a workout cost of $0.755 per share, which amounts to the closing cost of the business’s typical stock on May 1, 2025. Each stock choice has a ten-year term and will vest regarding 25% of the shares underlying the stock choice on the very first anniversary following beginning of work, and the staying 75% of the shares underlying the stock choice will vest in 36 equivalent regular monthly installations afterwards, based on ongoing service with the business or any of its subsidiaries through each relevant vesting date.
The stock choices go through the terms of Xilio Rehabs’ 2022 Temptation Stock Reward Strategy, along with the terms of the stock choice arrangement covering the grant and were made as an incentive product to the specific participating in work with the business in accordance with Nasdaq Listing Guideline 5635( c)( 4 ).
About Xilio Rehabs
Xilio Rehabs is a clinical-stage biotechnology business finding and establishing tumor-activated, or masked, immuno-oncology (I-O) treatments with the objective of substantially enhancing results for individuals dealing with cancer without the systemic negative effects of present I-O treatments. The business is leveraging its exclusive platform to advance a pipeline of unique, tumor-activated I-O particles that are developed to enhance the healing index by localizing anti-tumor activity within the growth microenvironment. Discover more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Rehabs, Inc).
Financier and Media Contact:
Scott Young
Vice President, Financier Relations and Corporate Communications
investors@xiliotx.com
Market News and Data gave you by Benzinga APIs